<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0375">
 <label>75</label>
 <element-citation publication-type="journal" id="sbref0375">
  <person-group person-group-type="author">
   <name>
    <surname>Hirota</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Shimosegawa</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Kitamura</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Takeda</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Takeyama</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Mayumi</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pan-creatitis: a multicenter, randomized, open-label, phase 2 trial</article-title>
  <source>J Gastroenterol</source>
  <volume>55</volume>
  <issue>3</issue>
  <year>2020</year>
  <fpage>342</fpage>
  <lpage>352</lpage>
  <pub-id pub-id-type="pmid">31758329</pub-id>
 </element-citation>
</ref>
